State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3

Siebert, Uwe, Alagoz, Oguzhan, Bayoumi, Ahmed M., Jahn, Beate, Owens, Douglas K., Cohen, David J., Kuntz, Karen M.·2012·Value in Health
DOI 10.1016/j.jval.2012.06.014

Cited by (494)

Items 401–494 of 494

  1. Hydrogel spacers in external beam radiation therapy of prostate cancer: Patient selection and cost-effectiveness
    Scott Jones · 2020 · Queensland University of Technology
  2. Validation of a decision-analytic model for the cost-effectiveness analysis of a risk-stratified National Breast Screening Programme in the United Kingdom
    Stuart James Wright, Ewan Gray, G Rogers, Anna Donten, Katherine Payne · 2022 · medRxiv
  3. Management of Moderate-to-highly Exuding Leg Ulcers with Superabsorbent Wound Dressings versus Foams Dressings in Spanish Settings: An Early-stage Cost-effectiveness and Budget-impact Analyses
    Vladica M. Veličković, Joan Enric Torra‐Bou, Francisco Cegri Lombardo, Federico Palomar Llatas · 2023 · medRxiv
  4. Unlocking Efficient Hospital Operations: Discrete Event Simulation in R
    Mohamed Kamal, Omneya Hassanain · 2023 · medRxiv
  5. Gastroesophageal adenocarcinoma
    Karen van der Sluis · 2024
  6. Economic evaluation of wearable fitness trackers versus metformin for preventing type 2 diabetes in the UK population
    Xu, Yihan, García-Lorenzo, Borja · 2025 · BMC Digital Health
  7. Efficiency and Variance Reduction
    J. Jaime, Jörgen Möller, Jonathan Karnon, James Stahl, Jack Ishak · 2015 · Chapman & Hall/CRC eBooks
  8. Individual-Level Simulation Model For Cost Benefit Analysis In Healthcare
    Nagesh Shukla, Vu Lam Cao, Van Phuong Hoang, Marian Shanahan, Allison Ritter, Pascal Perez · 2016 · European Conference on Modelling and Simulation (ECMS)
  9. Genetic algorithm based transition probabilities estimation
    Xiuxian Wang, Na Geng, Zhibin Jiang · 2017
  10. A theoretical foundation of state-transition cohort models
    Rowan Iskandar · 2018 · bioRxiv (Cold Spring Harbor Laboratory)
  11. Early Treatment in HCV: Is it a Cost-Effective Option from the Italian Perspective?
    Andrea Marcellusi, Raffaella Viti, Francesco Damele · 2016 · SSRN Electronic Journal
  12. XYZ-analysis to determine doctors' influence on the pharmacy assortment of OHD in the Podolsky region of Ukraine
    Т. I. Іvko · 2014 · Journal of Health Policy & Outcomes Research
  13. Cost-Effectiveness of Guideline-Based Care for Venous Leg Ulcers in Australia
    Qinglu Cheng · 2019 · Queensland University of Technology
  14. Exclusive human milk diet for very preterm babies in England: protocol for a cost-effectiveness and budget impact analysis
    Chris Sampson, Kyann Zhang, David William Parkin · 2021 · F1000Research
  15. Cost-effectiveness and work ability in colorectal cancer
    Mira D. Franken · 2021
  16. A conceptual modelling framework for estimating the consequences of psoriatic arthritis disease domains
    Jacquelyn W. Chou, Ervant J. Maksabedian Hernandez, David H. Collier · 2021 · medRxiv
  17. Analysis of Cost-Effectiveness of Trametinib Plus Dabrafenib as First-Line Therapy for Metastatic BRAF V600-Mutated Melanoma in China
    Guojun Sun, Jingwen Wang, Xiaoying Zhou · 2021 · Research Square
  18. Cost-effectiveness of subcutaneous house dust mite allergen immunotherapy plus pharmacotherapy for allergic asthma
    D. Parra Padilla, Josefina Zakzuk, M. Carrasquilla et al. · 2020
  19. Individual-Level Simulation Model For Cost Benefit Analysis In Healthcare
    Nagesh Shukla, Vu Lam Cao, Van Phuong Hoang, Marian Shanahan, Allison Ritter, Pascal Perez · 2016 · European Conference on Modelling and Simulation (ECMS)
  20. 1008 How to model temporal changes in comorbidity for cancer patients using prospective cohort data
    Mieke Van Hemelrijck, L. Lindhagen, David Robinson · 2015 · European Journal of Cancer
  21. Faculty Opinions recommendation of Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: A modeling study.
    George T. Cholankeril · 2019 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  22. Literatur zu Schwartz F.W. et al.: Public Health – Gesundheit und Gesundheitswesen
    2012 · Elsevier eBooks
  23. Health Technology Assessment ( HTA ) Using MAFEIP (Monitoring and Assessment Framework for the European Innovation Partnership on Active and Healthy Ageing)
    Francisco Lupiáñez‐Villanueva, Frans Folkvord, Nuria Febrer, Laura Gunderson · 2022 · The International Encyclopedia of Health Communication
  24. Pharmacoeconomics
    Richard C. Dodel, Christopher Kruse, Annette Conrads‐Frank, Uwe Siebert · 2022 · Springer eBooks
  25. Quantitative Calculation in Medical Decision-Making and Human Persuasion: Decision Sciences, Big Data, Computer Decision Aids, Medical Calculators, and Artificial Intelligence
    Vic Velanovich · 2023 · Springer eBooks
  26. Efetividade e custo-efetividade da braquiterapia guiada por imagem 3D versus braquiterapia convencional (2D) em pacientes com câncer do colo uterino
    Érica Aranha Suzumura · 2023
  27. Cost-effectiveness of repeat delayed imaging for spontaneous subarachnoid hemorrhage
    Wenru Shang, Huajie Jin, Amisha Vastani · 2023 · PLoS ONE
  28. Active Learning for Speeding Up Numerical Experiments in Sensitivity Analysis and Simulation Calibration
    Sabrina Angco · 2023
  29. Active Learning for Speeding Up Numerical Experiments in Sensitivity Analysis and Simulation Calibration
    Sabrina Angco · 2023
  30. Cost-effectiveness and health impact of screening and treatment of Mycobacterium tuberculosis infection among formerly incarcerated individuals in Brazil
    Ana van Lieshout Titan, Fayette Klaassen, Daniele Maria Pelissari et al. · 2024 · medRxiv
  31. Economic evaluation of a wearable-based intervention to increase physical activity among insufficiently active middle-aged adults
    Jack Ching, Steve Duff, John Hernandez · 2024 · medRxiv
  32. Data-driven Huntington’s disease progression modelling and estimation of societal cost in the UK
    Andrew Pollard, Danica Vukadinović Greetham, James Myatt, Hugh Edward Rickards, Cath A. Stanley, Dave Dungate · 2024 · Royal Society Open Science
  33. Exploratory analysis of the economically justifiable price of tezepelumab for asthma severe in Colombia
    Jefferson Antonio Buendía, Andrés Felipe Zuluaga · 2024 · Journal of Asthma
  34. tatooheene: Technology Appraisal Toolbox for Health Economic Evaluations in the Netherlands
    Stijn Peeters, Eline Krijkamp, Frederick W.F. Thielen · 2024
  35. Análise de custo-efetividade do mundo real da timoglobulina versus ausência de terapia de indução em receptores de transplante renal com baixo risco de perda do enxerto
    Adrieli Barros Bessa, Marina Pontello Cristelli, Cláudia Rosso Felipe · 2024 · Brazilian Journal of Nephrology
  36. Forecasting stroke and stroke-driven dementia in a rapidly ageing population: a model-based analysis of alternative projection scenarios for Ireland
    Eithne Sexton, Martín O’Flaherty, Anne Hickey, David James Williams, Frances Horgan, Chris Macey, Suzanne Timmons, Rónán Collins, Kathleen Bennett · 2025 · BMJ Open
  37. Cost-Effectiveness Analysis of Angiotensin Receptor Neprilysin Inhibitor Compared With Angiotensin-Converting Enzyme Inhibitor Among Patients With Heart Failure With Reduced Ejection Fraction in Malaysia
    Wai-Chee Kuan, Zanfina Ademi, Sit Wai Lee et al. · 2025 · Value in Health Regional Issues
  38. Development, calibration, and external validation of a semi-Markov model for hypertension in older adults with Medicare coverage in the United States
    Mahip Acharya, Corey J. Hayes, CARI ANNE BOGULSKI · 2025 · medRxiv
  39. Adjuvante Immuntherapie mit Pembrolizumab beim Nierenzellkarzinom – ist der neue Therapiestandard auch kosteneffektiv?
    Sarah Katharina Assiba Weiß, Carsten Lange, Nicole Hübscher · 2025 · Die Urologie
  40. Simulation Modeling of Oral Cancer Development with Risk Stratification: How Potential Screening Programs Can Be Evaluated
    Mutita Siriruchatanon, Emily Brooks, Alexander Ross Kerr · 2025 · MDM Policy & Practice
  41. Disease Management Program for the Care of Hypertensive Patients Using Telemedical Support
    Christian Koppelstätter, Edmund Bode, Bettina Fetz, Barbara Haselwanter, Florian Hoffmann, Andreas Huber, Gert J. Mayer, Robert Modre‐Osprian, Sabine Perl, Sibylle Puntscher et al. · 2025 · Wiener klinisches Magazin
  42. Additional file 1 of Testing strategies for couple engagement in prevention of mother-to-child transmission of HIV and family health in Kenya: study protocol for a randomized controlled trial
    Zachary Kwena, Liza Kimbo, Lynae A. Darbes et al. · 2021 · Figshare
  43. Additional file 1 of A long-term cost-effectiveness analysis of cardiac resynchronisation therapy with or without defibrillator based on health claims data
    Moritz Hadwiger, Laura Schumann, Nora Eisemann, Dagres, Nikolaos, Hindricks, Gerhard, Janina Haug, Wolf, Michael, Marschall, Ursula, Alexander Katalinic, Frielitz, Fabian-Simon · 2022 · Figshare
  44. Additional file 2 of Testing strategies for couple engagement in prevention of mother-to-child transmission of HIV and family health in Kenya: study protocol for a randomized controlled trial
    Zachary Kwena, Liza Kimbo, Lynae A. Darbes et al. · 2021 · Figshare
  45. Additional file 2 of Impact of limited sample size and follow-up on single event survival extrapolation for health technology assessment: a simulation study
    Jaclyn Marie Beca, Chan, Kelvin K. W., Naimark, David M. J. · 2021 · Figshare
  46. Additional file 1 of Decision-analytic evaluation of the comparative effectiveness and cost-effectiveness of strategies to prevent breast and ovarian cancer in German women with BRCA-1/2 mutations
    Lára R. Hallsson, Gaby Sroczynski, Engel, Jutta, Siebert, Uwe · 2023 · Figshare
  47. Additional file 1 of The conceptualisation of cardiometabolic disease policy model in the UK
    Putri, Septiara, Giorgio Ciminata, Lewsey, Jim, Jani, Bhautesh, McMeekin, Nicola, Claudia Geue · 2024 · Figshare
  48. Additional file 2 of The conceptualisation of cardiometabolic disease policy model in the UK
    Putri, Septiara, Giorgio Ciminata, Lewsey, Jim, Jani, Bhautesh, Nicola McMeekin, Claudia Geue · 2024 · Figshare
  49. Additional file 1 of Cost-effectiveness of a hybrid emergency room system for severe trauma: a health technology assessment from the perspective of the third-party payer in Japan
    Kinoshita, Takahiro, Moriwaki, Kensuke, Nao Hanaki · 2021 · Figshare
  50. Additional file 2 of Decision-analytic evaluation of the comparative effectiveness and cost-effectiveness of strategies to prevent breast and ovarian cancer in German women with BRCA-1/2 mutations
    Lára R. Hallsson, Gaby Sroczynski, Engel, Jutta, Siebert, Uwe · 2023 · Figshare
  51. Additional file 1 of High-precision stereotactic irradiation for focal drug-resistant epilepsy versus standard treatment: a randomized waitlist-controlled trial (the PRECISION trial)
    Zegers, C. M. L., Ans C. C. Swinnen, Cheryl Roumen, Aswin Louis Hoffmann, Esther G.C. Troost, Charlotte J.J. van Asch, Lloyd Brandts, Inge Compter, Dieleman, E. M. T., Jeanette B. Dijkstra et al. · 2024 · Figshare
  52. Additional file 3 of Decision-analytic evaluation of the comparative effectiveness and cost-effectiveness of strategies to prevent breast and ovarian cancer in German women with BRCA-1/2 mutations
    Lára R. Hallsson, Gaby Sroczynski, Engel, Jutta, Siebert, Uwe · 2023 · Figshare
  53. Additional file 1 of Impact of limited sample size and follow-up on single event survival extrapolation for health technology assessment: a simulation study
    Jaclyn Marie Beca, Chan, Kelvin K. W., Naimark, David M. J. · 2021 · Figshare
  54. Additional file 1 of Comparison of partitioned survival modeling with state transition modeling approaches with or without consideration of brain metastasis: a case study of Osimertinib versus pemetrexed-platinum
    Shim, Yoon-Bo, Oh, Byeong-Chan, Lee, Eui-Kyung, Park, Mi-Hai · 2024 · Figshare
  55. Additional file 4 of Impact of limited sample size and follow-up on single event survival extrapolation for health technology assessment: a simulation study
    Jaclyn Marie Beca, Chan, Kelvin K. W., Naimark, David M. J. · 2021 · Figshare
  56. Additional file 1 of Cost-effectiveness of left atrial appendage closure for stroke prevention in atrial fibrillation: a systematic review appraising the methodological quality
    Hewage, Sumudu A., Rini Noviyani, David Brain, Pakhi Sharma, William Anthony Parsonage, Steven McPhail, Adrian Gerard Barnett, Kularatna, Sanjeewa · 2023 · Figshare
  57. Additional file 3 of Impact of limited sample size and follow-up on single event survival extrapolation for health technology assessment: a simulation study
    Jaclyn Marie Beca, Chan, Kelvin K. W., Naimark, David M. J. · 2021 · Figshare
  58. Additional file 1 of Cost-effectiveness analysis of a strategy to delay progression to dialysis and death among chronic kidney disease patients in Lima, Peru
    Saldarriaga, E. M., Bravo-Zúñiga, J., Hurtado-Roca, Y. · 2021 · Figshare
  59. Cost-Utility and Budget Impact Analysis of Pharmacogenetic-Guided Antiplatelet Therapy for Acute Coronary Syndrome in Thailand
    Nathapol Samprasit, Nattanichcha Kulthanachairojana, Chamipa Phanudulkitti, Jatapat Hemapanpairoa · 2025 · Value in Health Regional Issues
  60. In Silico Evaluation of Algorithm-Based Clinical Decision Support Systems Based on Care Pathway Simulation Models: Scoping Review
    Michael Dorosan, Ya-Lin Chen, Yan He, Qingyuan Zhuang, Shao Wei Lam · 2026 · JMIR AI
  61. A Governance-Driven, Real-World Data-Calibrated Health Informatics Framework for Longitudinal Utilization Forecasting in Oncology and Complex Chronic Conditions
    Appala Venkata Subhadra Raju Dantuluri, Sumit Kumar · 2026 · medRxiv
  62. Economic evaluation of a digital symptom checker for endometriosis using a Markov decision process model
    Yihan Xu, Carley Prentice, Sergio Torres Rueda, András Meczner, Jan Multmeier, Aidan P. Wickham, Laura Kelly, Anna Klepchukova, Heorhi Stsefanovich, Liudmila Zhaunova · 2026 · npj Digital Medicine
  63. Cost–Utility Analysis of Inclisiran Added to Standard of Care for Secondary Prevention of Cardiovascular Disease in Egypt: A Public Payer Perspective
    Mahmoud Almezayen · 2026 · Research Square
  64. Health as a Financial Asset: A Decision-Theoretic Framework for Individual Health Capital Management
    Mauro Iannopollo · 2026 · Research Square
  65. Coût-efficacité des stratégies vaccinales en France, exemple de trois pathologies infectieuses : le tétanos, la rage et les infections materno-fœtales à cytomégalovirus
    Dieynaba S. N’Diaye · 2014
  66. Development of a discrete event simulation model for health economic evaluation of interventions for patients with schizophrenia
    Junwen Zhou · 2020
  67. Decision analysis for the long-term effectiveness of a community-based intervention to prevent obesity: an EUREGIO project
    Júlia Santamaria, Beate Jahn, Gaby Sroczynski, Kieran Michael Tuohy, Veronika Papon, Uwe Siebert, Nikolai Mühlberger · 2026 · Journal of Public Health
  68. Implementing a CYP2C19-guided approach for prescribing dual antiplatelet therapy in acute coronary syndrome for patients undergoing percutaneous coronary intervention: a cost-effectiveness analysis
    Alireza Mahboub Ahari, Joe Hilton, Maria Rodrigues · 2026 · Research Square
  69. Cost-Effectiveness of Radiotherapy and Its Impact on Patient Quality of Life: A Real-World Cost Utility Analysis in Greece
    Elissavet Vardaki, Maria Tolia, Christos Michalakelis · 2026 · Current Oncology
  70. A guide to critical reading of influenza vaccine cost-effectiveness analyses
    Raúl Ortíz de Lejarazu, Esther Redondo Margüello, Ángel Gil de Miguel, Federico Martinón‐Torres, Javier Díez‐Domingo, Juan Luis López-Belmonte Claver, Ariadna Diaz-Aguiló, J. Manel Farré Avellà, Paloma I. Palomo Jiménez, José María Abellán Perpiñán · 2026 · Global & Regional Health Technology Assessment
  71. A Cost–Utility Analysis of Two-Stage Screening Strategies Based on Waist-to-Height Ratio for Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in China
    Y F Liu, Tianyu Huang, Jiajia Dang, S L Cai, Jiaxin Li, Ruolan Yang, J H Zhang, Kaiheng Zhu, Ziyue Sun, Yang Yang et al. · 2026 · Healthcare
  72. State-transition and simulation-based modeling approaches for simulating the progression of dental caries: a scoping review
    Xenia Teplitzky, Darja Gostilo, Georgios Tsilingaridis, Blend Hamza, Lina Petrova, Shaju Jacob Pulikkotil · 2026 · Frontiers in Oral Health
  73. Beta-3 Agonists Versus Anticholinergics: A Cost-effectiveness Analysis
    Brad St. Martin, Shannon L. Wallace, Lauren A. Cadish · 2025 · Urogynecology
  74. An Early Trial‐Based Cost‐Effectiveness Analysis of Extracorporeal Shockwave Therapy for Diabetes Related Foot Ulcer Healing
    L. Hitchman, M. Siciliano, R. Lathan, B. Ravindhran, M. Sidapra, J. Long, G. Smith, M. Twiddy, D. Russell, I. Chetter et al. · 2026 · International Wound Journal
  75. Model-based cost-effectiveness analysis of [18F]FDG PET/CT early into therapy with immune checkpoint inhibitors: Tackling pseudoprogression in unresectable cutaneous melanoma patients
    Sietse van Mossel, S. Saing, D. Vriens · 2026 · The EANM Journal
  76. Economic evaluation of the Healthy Early Life Moments in Singapore (HELMS) programme: a study protocol for an integrated lifestyle intervention supported by a mobile health tool for mothers and children in Singapore
    Kyaw Zay Ya, Chee Wai Ku, See Ling Loy, Annabel Ngien, Kai Ting Mok, Mei Chien Chua, Fabian Yap, Jerry Kok Yen Chan, Elizabeth Kate Martin · 2026 · BMJ Open
  77. Cost-Effectiveness of Recombinant Versus Live-Attenuated Herpes Zoster Vaccination in China: A Modeling Study Under Self-Paid and National Immunization Scenarios
    Wei Zhang, Song Li, Tianming Yan · 2026 · Vaccines
  78. Cost-Utility Analyses of Systemic Treatments for Psoriasis and Psoriatic Arthritis in the UK: A Systematic Review of Modelling Methods
    Thomas S. Clemmet, Duc Binh Phan, Alice Copson · 2026 · PharmacoEconomics
  79. A conceptual framework linking health related costs of PFAS pollution to the polluter pays principle
    Zoë Vandamme, Brigitte Reimann, Bo Vandenbulcke · 2026 · iScience
  80. Quantitative analytical frameworks for benefit-risk assessment in health technology assessment
    Érica Aranha Suzumura, Aline Frossard Ribeiro Bortoluzzi, Ana Carolina Nonato · 2026 · Epidemiologia e Serviços de Saúde
  81. Estruturas analíticas quantitativas para avaliação benefício-risco na avaliação de tecnologias em saúde
    Érica Aranha Suzumura, Aline Frossard Ribeiro Bortoluzzi, Ana Carolina Nonato · 2026 · Epidemiologia e Serviços de Saúde
  82. An Empirical Comparison of Statistical Methods for Estimating EQ-5D Health State Utilities in Rheumatoid Arthritis Clinical Trials for Economic Modelling
    Jiajun Yan, Eleanor Pullenayegum, Shun Fu Lee, Feng Xie · 2026 · Research Square
  83. Enhancing Military Architectural Frameworks with Method Chunks: A Modular Approach to Agile C2-System Design
    Jan Lundberg, Kent Andersson, Jānis Stirna · 2026 · Complex Systems Informatics and Modeling Quarterly
  84. Cost-utility analysis of home treatment versus inpatient treatment in child and adolescent psychiatry: a decision analysis
    Karolina Foremnik, Gaby Sroczynski, Barbara Buchberger · 2026 · Frontiers in Child and Adolescent Psychiatry
  85. Cost-effectiveness of digitoxin in heart failure with reduced ejection fraction in the European Union and the United States
    Priyanka Boettger, Anika Großhennig, Stefan Störk et al. · 2026 · European Journal of Heart Failure
  86. Cost-Utility Analysis of First-Line Olaparib plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer in China after Volume-Based Procurement
    Hanqian Dai, Lijuan Jiang, Qiutao Gu, Chiyi Yao, Dandan Yu, Aidong Chao, Junwen Xie, Hui Xu, Ning Zhu, Bo Zhao et al. · 2026 · medRxiv
  87. Observation versus coiling for unruptured intracranial aneurysms in octogenarians: A decision-analytic modeling study
    Hyun Dong Yoo, Jae Guk Kim, Seung Young Chung · 2026 · PLoS ONE
  88. Cost-effectiveness of nicotine metabolite ratio-guided smoking cessation therapy in China: a hybrid decision-analytic modeling study based on real-world data
    Anqi Cheng, Min Wang, Yingman Gao, Tingfen Ji, Xuejun Hu, Xue Yu, Yong Qi, Wenli Chen, Suqin Xu, Zhao Liu et al. · 2026 · Journal of Medical Economics
  89. Economic evaluation of primary health care integration and targeted mass drug administration in counties in western Kenya
    Josphat M. Muchangi, W. Omondi, Meshack Ndirangu, C. Karutu, Irene Chami, G. Wangalwa, M. Ofire, R. Ofwete, K. Kithuki, Nelly Saiti et al. · 2026 · Frontiers in Health Services
  90. Comparative effectiveness of nature-based social prescribing to alleviate loneliness in Spain: a decision analysis informed by the RECETAS trial
    Veronika Papon, Beate Jahn, Gaby Sroczynski, Jill Litt, Laura Coll‐Planas, Montse Masó-Aguado, Marjan Arvandi, Júlia Santamaria, Igor Kuchin, Sibylle Puntscher et al. · 2026 · Frontiers in Psychology
  91. Cost-Effectiveness of Annual Atrial Fibrillation Screening Compared with Current Opportunistic Screening in Australian Primary Care: A Model-Based Economic Evaluation
    Ureni Halahakone, Sameera Jayan Senanayake, Victoria McCreanor, William Anthony Parsonage, David Brain · 2026 · Applied Health Economics and Health Policy
  92. Cost-effectiveness of RIMS1 methylation-guided gastric cancer surveillance after Helicobacter pylori eradication
    Yifan Qiu, Xianzhu Zhou, Hao Hu et al. · 2026 · Expert Review of Pharmacoeconomics & Outcomes Research
  93. Conceptualising Health Economic Models Using a Graph Retrieval-Augmented, Agentic AI Framework with Human-in-the-Loop Validation: Proof-of-Concept Study
    Tushar Srivastava, Hanan Irfan, Shilpi Swami · 2026 · PharmacoEconomics - Open
  94. Real-world cost-effectiveness of sequential therapy of in-class transition to ixazomib versus daratumumab for transplant-ineligible newly diagnosed multiple myeloma in China
    Genyong Zuo, Aijun Liu, Zunmin Zhu et al. · 2026 · Journal of Comparative Effectiveness Research